{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["PT-112"]],"indication":"thymoma and thymic carcinoma","name":"NCT05104736","nct_id":"NCT05104736","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05104736. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"PT-112 will be administered intravenously in 28-day cycles, on Days 1 and 15 at a dose of 360 mg/m2 for cycle 1, and on day 1 at 250mg/m2 for each subsequent cycle, until disease progression, development of intolerable adverse events, or until 8 years after an individual participant has been on study","label":"PT-112","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"conditions":["Thymic Epithelial Tumor","Recurrent Thymoma","Thymic Cancer"],"enrollment":{"count":53,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"PT-112","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"overall response rate (ORR)","timeFrame":"assessed every 8 weeks while on treatment and then every 3 months after that for a maximum of 8 years from the start of study"}],"references":[],"start_date":{"date":"2022-04-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PT-112 in Subjects With Thymoma and Thymic Carcinoma","url":"https://clinicaltrials.gov/study/NCT05104736"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05104736"}